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ABSTRACT
The vascular endothelial growth factor receptor 1 (VEGFR-1) family of receptors 
is preferentially expressed in endothelial cells, with the full-length and mostly the 
soluble (sVEGFR-1) isoforms being the most expressed ones. Surprisingly, cancer 
cells (MDA-MB-231) express, instead, alternative intracellular VEGFR-1 variants. We 
wondered if these variants, that are no longer dependent on ligands for activation, 
were expressed in a physiological context, specifically in spermatogenic cells, and 
whether their expression was maintained in spermatozoa and required for human 
fertility. By interrogating a human library of mature testis cDNA, we characterized two 
new truncated intracellular variants different from the ones previously described in 
cancer cells. The new isoforms were transcribed from alternative transcription start 
sites (aTSS) located respectively in intron-19 (i19VEGFR-1) and intron-28 (i28VEGFR-1) 
of the VEGFR-1 gene (GenBank accession numbers JF509744 and JF509745) 
and expressed in mature testis and spermatozoa. In this paper, we describe the 
characterization of these isoforms by RT-PCR, northern blot, and western blot, their 
preferential expression in human mature testis and spermatozoa, and the elements 
that punctuate their proximal promoters and suggest cues for their expression in 
spermatogenic cells. Mechanistically, we show that i19VEGFR-1 has a strong ability to 
phosphorylate and activate SRC proto-oncogene non-receptor tyrosine kinases and 
a significant bias toward a decrease in expression in patients considered infertile by 
WHO criteria.
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INTRODUCTION
During meiotic and post-meiotic stages of 
spermatogenesis, the genome is reprogrammed prior to 
packaging. Simultaneously, new mRNAs responsible for 
active and precise synthesis of proteins are transcribed with 
stage specific precision. Selected transcripts and proteins, 
essential for spermatozoa activity, fertilization or embryo 
development are retained in the spermatozoa [1, 2].
Many spermatogenic transcripts are produced 
from alternative transcription start sites and alternative 
splicing of the 5′UTR. Although these mRNAs may code 
for proteins identical to their somatic counterparts, they 
often differ, from the corresponding somatic transcripts, 
in regulatory potential [3, 4].
Protein tyrosine kinases (PTKs) are key factors 
regulating spermatogenesis, essential for differentiation, 
migration, adhesion, spermatid shaping, motility and 
capacitation. In addition to the general requirement for 
PTKs, normal spermatogenesis and spermiogenesis also 
seem to be dependent on the expression of truncated 
isoforms [5]. Truncated proteins, many of them protein 
kinases, either coexist with full-length partners or replace 
them. For example, the KIT proto-oncogene receptor 
tyrosine kinase is highly expressed in spermatogonia and 
is replaced by the truncated-intracellular KIT version (Tr-
KIT) during spermiogenesis [6–9]. Interestingly, there is a 
high degree of similarity between VEGFR-1 and KIT, and 
between i
19
VEGFR-1 and Tr-KIT.
Vascular endothelial growth factor receptor 1 
(VEGFR-1), also known as FLT-1 (fms related tyrosine 
kinase 1) is a high-affinity and low-activity (relatively 
to VEGFR-2) tyrosine kinase receptor of the vascular 
endothelial growth factor VEGF-A, and binds selectively 
to ligands VEGF-B and placental growth factor (PlGF) 
[10–13]. Expression of the VEGFR-1 receptor occurs 
mainly in endothelial cells, but also takes place in different 
types of non-endothelial cells [14, 15], including mouse 
spermatids and spermatozoa [16].
VEGFR-1 in humans consists of 30 exons spanning 
more than 193 kb [17]. Two extracellular soluble isoforms, 
sVEGFR-1 and s14VEGFR-1, end in exons generated by 
extending into intron 13 (sVEGFR-1) or jumping into intron 
14 (s14VEGFR-1) [18, 19]. In addition, we have characterized 
several intracellular isoforms of VEGFR-1 expressed in cancer 
cells [20].
In mouse [16], the vascular endothelial growth 
factor receptor 2 (VEGFR-2), the high-activity and low-
affinity receptor for VEGF-A, comparatively to VEGFR-1 
(also known as KDR, kinase insert domain receptor) is 
expressed in type A spermatogonia, while VEGFR-1 is 
not expressed until the pachytene spermatocyte and round 
spermatid stages. There is no knowledge of the specific 
VEGFR-1 isoforms expressed in mouse spermatogenic 
cells, and contrary to human [20], no truncated isoforms 
of the VEGFR-1 receptor are known to be expressed.
In this paper, we have identified two intracellular 
isoforms of the VEGFR-1 receptor in mature testis and 
spermatozoa. We have named them i
19
VEGFR-1 and 
i
28
VEGFR-1, as they start transcription in intron 19 and 28, 
respectively, and we have characterized them by sequencing, 
RT-PCR, northern and western blot. Mechanistically, 
we have demonstrated, using binding experiments and 
transfection of recombinant plasmids in CHO and HEK293 
cells, that i
19
VEGFR-1 is able to bind and strongly 
phosphorylate and activate SRC protein kinases.
As a preliminary study, due to sample scarcity and 
the lack of confident parameters for fertility, we have 
analyzed by Real time-PCR, the expression of both 
isoforms in samples of astenozoospermic, oligozoospermic 
or oligoastenozoospermic patients relative to 
normozoospermic samples (WHO parameters) [21]. We 
wanted to assess the predictive potential of their expression 
as a marker for male infertility, a major problem worldwide 
because of inaccurate diagnosis, much dependent on 
empirical evidence and unreliable parameters.
We have also explored by an in silico approach, 
taking advantage of the huge quantity of available data 
in well-documented networks and testis cell lines, the 
chromatin landscape and the response element present in 
the corresponding proximal promoters around the TSS, of 
both isoforms. The reported results showed a relatively 
open chromatin configuration, punctuated by activating 
marks signatures and regulatory DNA sequence elements, 
which may allow for transcription in post-meiotic cells.
Taken together, the two i
19
VEGFR-1 and i
28
VEGFR-1 
isoforms described in this paper may represent haploid cell 
specifically expressed transcripts that function as convenient 
ligand-independent intracellular factors with interest in 
fertility and fertilization.
RESULTS
Identification of two novel intracellular 
truncated C-terminal isoforms of VEGFR-1
A search by Rapid amplification of cDNA ends 
(RACE5′ and RACE3′) for truncated intracellular isoforms 
of the VEGFR-1 receptor, failed to detect previously 
characterized intracellular isoforms [20] of the VEGFR-1 
receptor in mature human testis and spermatozoa. We also 
interrogated a mouse mature testis cDNA library and could 
not find any truncated isoform of the VEGFR-1 receptor. 
In contrast, the same analysis, by rapid amplification 
of c-DNA ends (RACE), RACE5′ and RACE3′, of a 
mature testis human cDNA library, allowed us to obtain 
two novel truncated intracellular isoforms variants of the 
VEGFR-1 receptor. We named these intracellular isoforms 
i
19
VEGFR-1 and i
28
VEGFR-1, the number indicating the 
intron where the aTSS is located (Figure 1).
Both isoforms lack the sequences for extracellular 
domains, transmembrane domain and either, part of the 
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kinase domain (i
19
VEGFR-1) or the whole kinase domain, 
leaving only a sequence coding for a C-terminal tail of 
85 amino acids in the case of i
28
VEGFR-1. Both isoforms 
incorporate new leader 5′UTR sequences (Figure 1A). For 
the 3′UTR, we obtained a sequence of 675 nucleotides, 
finishing in a rich poly (A) sequence. This 3′UTR is 
much shorter than the canonical VEGFR-1 3′UTR 
observed in endothelial cells. Northern blot reinforced 
the predominance of this 3′UTR (as mentioned later), 
also showing the existence, in much lower amounts of the 
longer canonical 3′UTRs.
Isoform i
19
VEGFR-1 starts at nucleotide 1,200 
of intron 19 of the full-length VEGFR-1 receptor, in a 
T nucleotide that is followed by a sequence element, 
where 19 nucleotides out of 21 matches the p53 sequence 
element [22] (red in Figure 1A). This motif can form 
a hairpin structure (Figure 1A). The first exon of this 
isoform has a conserved splice site (gt) that jumps to the 
second exon acceptor site (ag), generating a VEGFR-1 
isoform of 12 exons, the last 11 corresponding to exons 
20 to 30 of the full length VEGFR-1. The 5′UTR of the 
new isoform, is 129 nucleotides long, and shows two out 
of frame uORFs (Figure 1A).
The putative i
19
VEGFR-1 transcript encodes a 
protein of 433 amino acids, from amino acid 906 to 
amino acid 1,338 of the full-length VEGFR-1 receptor, 
with a predicted molecular weight of 49.4kDa; isoform 
i
19
VEGFR-1 conserves 253 of the 332 amino acids of 
the kinase domain. It has lost most of the ATP-binding 
domain, but it conserves the phosphotransferase site as 
well as eight tyrosine-phosphorylation sites (Figure 1B 
and Figure 2).
Isoform i
28
VEGFR-1 starts at nucleotide 308 of 
intron 28 of the full-length VEGFR-1, in a very rich 
polypyrimidine stretch. The first exon of this isoform has 
a conserved splice site (gt) that jumps to the second exon 
acceptor site (ag), generating a small VEGFR-1 isoform 
of 3 exons, the last 2 corresponding to exons 29-30 of the 
full-length VEGFR-1. The 5′UTR of the new isoform is 
135 nucleotides long. The putative i
28
VEGFR-1 encodes a 
protein of 85 amino acids, from amino acid 1,254 to amino 
acid 1,338 of the full-length VEGFR-1 receptor, with a 
molecular weight of 9.5kD. The i
28
VEGFR-1 isoform 
lacks the entire kinase domain (Figure 1B), and conserves 
the last 3 phosphotyrosine sites (Figure 2).
Expression of i19VEGFR-1 and i28VEGFR-1 
isoforms in human mature testis, cryptorchidic 
testis, spermatozoa, and HUVEC cells, relative 
to the expression of canonical VEGFR-1, full-
length and soluble variants, and in samples with 
accepted or altered WHO 2010 parameters
We analyzed the expression of i
19
VEGFR-1 and 
i
28
VEGFR-1 and of full-length VEGFR-1, sVEGFR-1 
and s14VEGFR-1 isoforms, by northern-blot and/or 
semi-quantitative manual PCR, and Real-Time PCR, in 
human mature testis, cryptorchidic testis, HUVEC cells (a 
positive control for VEGFR-1), and human spermatozoa.
Figure 3 shows the northern-blot results obtained 
from mature testis, cryptorchidic testis and endothelial 
HUVEC cells using total RNA and a probe from the kinase 
region (Table 1). The pattern of expression in testis differs 
entirely from endothelial cells. In HUVEC cells, full-
length VEGFR-1 mRNA is detected as a band of ≈6.9kb, 
and a second band at ≈4.7kb, corresponds to a truncated 
isoform. Cryptorchidic testis, devoid of spermatogenic 
differentiating cells, shows only, a very faint band 
of ≈6.9kb. The pattern of expression in mature testis 
correspond to bands of ≈4.7kb, ≈2.6kb and ≈1.5kb, all of 
them compatible with the expected sizes of i
19
VEGFR-1 
and i
28
VEGFR-1 transcript isoforms, having different 
3′UTR lengths, but preferentially using the short 3′UTR of 
675 nucleotides obtained by RACE3′ (3′S, Figure 3). The 
northern pattern results are also in accordance with the 
relative expression of transcripts obtained by quantitative 
RT-PCR.
By semi-quantitative, as well as by Real-Time 
PCR, we detected significant levels of i
19
VEGFR-1 
and i
28
VEGFR-1 transcripts only in mature testis and 
spermatozoa (Figure 4A–4D). Full-length and both soluble 
forms, sVEGFR-1 and s14VEGFR-1, were also detected 
by PCR amplification in testis and spermatozoa, although 
at levels much lower than in HUVEC cells (Compare 
Figure 4B and 4D to 4E).
Isoforms i
19
VEGFR-1 and i
28
VEGFR-1, as 
detected by Real-Time PCR, showed higher expression 
in spermatozoa than in testis, suggesting preferential 
expression in haploid spermatogenic cells. (Compare 
Figure 4B with Figure 4D).
Quantitative real-time PCR of i
19
VEGFR-1 and 
i
28
VEGFR-1 mRNA from spermatozoa obtained from 
astenozoospermic, oligozoospermic or oligoastenozoospermic 
semen samples revealed statistically significant lower levels 
of i
19
VEGFR-1 expression compared to normozoospermic 
semen samples (Figure 4F). Expression of i
28
VEGFR-1 was 
also investigated but, although there was a tendency towards 
decreased levels in infertile samples, they were no statistically 
significant (data not shown).
Western blotting was employed to determine 
whether i
19
VEGFR-1 and i
28
VEGFR-1 transcripts were 
translated into proteins.
Figure 5 shows the protein corresponding to the 
i
19
VEGFR-1 isoform. It was detected in spermatozoa 
using an anti-VEGFR-1 antibody from the C-terminal of 
the protein (Santa Cruz, see materials and methods and 
Table 2). Binding of the antibody at the corresponding 
size of 49kD competed with an epitope specific blocking 
peptide (Santa Cruz) from the same region indicating the 
specificity of the western blot bands shown in Figure 5. The 
peptide corresponding to 
i28
VEGFR-1, expected as a 9.5kD 
band, was not as consistently detected. It appears as a faint 
band suggestive of a quite unstable peptide. The cropped 
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Figure 1: (A) Exon assembly of i
19
VEGFR-1 and i
28
VEGFR-1 isoforms indicating start of transcription (arrows), specific first exon 
(yellow) and intron 1 (broken line with nucleotide’s number), followed by the exons shared with the full-length receptor, and the stop codon 
(TAG). Top left, whole exon 1 (capital letters) and first 22 nucleotides of exon 2 (lower case) of i
19
VEGFR-1. Exon 1 starting with the p53 
sequence element (in red), is depicted with the putative hairpin structure. The open reading frames (uORF) are indicated, highlighting the 
ATG codon, as well as the non-in-frame putative peptides in the leader 5′UTR sequence. Below, the complete first exon of i
28
VEGFR-1 
with the polypyrimidine stretch (underlined) at the start of transcription (arrow). (B) Gene and protein assembly. The 30 exons (small brown 
rectangles) spanning the full- length VEGFR-1 receptor, or the eleven (i
19
VEGFR-1) and two (i
28
VEGFR-1) coding exons, are shown on 
top of each schematic protein. From top to bottom, full-length protein of 1,338 amino acids (aa), i
19
VEGFR-1 intracellular isoform of 
432 aa, and i
28
VEGFR-1 intracellular isoform of 85 aa. Circles denote extracellular immunoglobulin domains not present in the intracellular 
variants; orange rectangles show the split kinase domain, or slightly trimmed kinase in i
19
VEGFR-1.
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Figure 2: (A) VEGFR-1 receptor proteins shown in their respective compartments, with the numbering of their tyrosine’s residues, which 
are found at high density within the intracellular domain. Extracellular (named soluble) VEGFR-1 proteins contain the immunoglobulin 
domains (green circles) and end in specific tails. The full-length transmembrane VEGFR-1 receptor contains the immunoglobulin domains, 
the transmembrane and the juxta-membrane domains, as well as the intracellular split kinase domain ending in a C-terminal tail. Intracellular 
isoforms contain the whole kinase domain, part of it, or non-kinase domain (i
28
VEGFR-1). (B) Box detailing distinctive characteristics for 
the different VEGFR-1 isoforms.
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Table 1: Primers, with indication of gene sequence, size, polarity and specificity
Primer Sequence Size Polarity/position in full-length VEGFR-1
HFE11U 5′CATCACTCAGCGCATGGCAAT3′ 21 mer Forward/exon 11
HFE12U 5′AGCACCTTGGTTGTGGCTGAC3′ 21 mer Forward/exon12
HFs13D 5′TTGTTGCAGTGCTCACCTCTGA3′ 22 mer Reverse/intron 13 sVEGFR-1 specific/splints exon and 
intron 13. 
HFE11U-
HFs13D
474 bp Detects sVEGFR-1. Skips intron11 and exon and intron 
12.
HFE12U-
HFs13D
428 bp Detects selectively sVEGFR-1 isoform.
Skips intron 12.
HFE14U 5′GATCAGGAAGCACCATACCTCCTG3′ 24 mer Forward/exon 14
HFs14D 5′GGTGATGATGACGATGACGATGG3′ 23 mer Reverse/intron 14, s14VEGFR-1 specific.
HFE14U-
HFs14D
191 bp Detects selectively s14VEGFR-1 isoform. Skips intron 14
HFe14U 5′TCCCCGAGCCTCAGATCACTTG3′ 22 mer Forward/exon 14
Flt1Fw 5′GATGTTGAGGAAGAGGAGGATT3′ 22 mer Forward/splints exons 21 and 22. 
Flt1Rv 5′AAGCTAGTTTCCTGGGGGTATA3′ 22 mer Reverse/exon 30, 3′UTR
Flt1Fw-
Flt1Rv
1,146 bp Probe synthesis
HFE15D 5′CTGGTTGGTGGCTTTGCAGTG3′ 21 mer Reverse/exon 15
HFE14U-
HFE15D
241 bp Detects full-length VEGFR-1 as well as isoforms with 
membrane and juxta-membrane domains.
HFI19U 5′CCCAGGCATGCAGTGGAAAC3′ 20 mer Forward/intron 19, i
19
VEGFR-1 specific
HF20D 5′CGTTTGCTCTTGAGGTAGTTGGAG3′ 24 mer Reverse/exon 20
HFI19U-
HF20D
190 bp Detects selectively i
19
VEGFR-1. Skips a large fragment 
of intron 19.
HFE22D 5′GACAGGAACTCCATGCCTCTGG3′ 22 mer Reverse/exon 22
HFI19U-
HF22D
457 bp Detects selectively i
19
VEGFR-1. Skips a large fragment 
of intron 19 plus exons and introns 20 and 21. 
HFI28U 5′CAGCTGTGTTCCTACCCAATCAC3′ 23 mer Forward/intron 28, i
28
VEGFR-1 specific
HFE30D 5′TCAGACAGCCCCGACTCCTTAC3′ 22 mer Reverse/exon 30
HFI28U-
HFE30D
197 bp Detects selectively i
28
VEGFR-1. Skips exon intron 29. 
HFE29U 5′GACTACCAGGGCGACAGCAGC3′ 21 mer Forward/exon 29
HFE30D 5′TCAGACAGCCCCGACTCCTTAC3′ 22 mer Reverse/exon 30
HFE29U- 
HFE30D
137 bp Amplifies all variants isoforms containing the C-terminal 
tail.
HCID 5′CAGCTGGAATGGCAGAAACTGG3′ 22 mer Reverse/exon 30
HFE29U-
HCID
170 bp Amplifies all variants isoforms containing the C-terminal 
tail.
HFrev2 5′GGCAAAAGCTAGTTTCCTGGGGGTATA3′ 27 mer Reverse/exon 30, 3′UTR.
19EAT 5′ATACAGAATTCGATGGTGATTGTTGAAT3′ 28 mer i
19
VEGFR-1 cloning
HFFP 5′GTCGTCATCCTTGTAATCGATGGGTGGG
GTGGAG3′
34 mer i
19
VEGFR-1 cloning plus partial flag tagging.
HFFFA 5′CAAGAGGGCCCTCACTTATCGTC 
GTCATCCTTGTA3′
35 mer i
19
VEGFR-1 cloning and complete flag tagging.
HAF 5′CCTCGCCTTTGCCGATCC3′ 18 mer Forward/endogenous β-Actin
HAR180 5′ATCACGCCCTGGTGCCTG3′ 18 mer Reverse/endogenous β-Actin
HAF-
HAR180
180 bp β-Actin. Skips intron.
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part of the blot correspond to a disturbing unspecific artifact 
present in both, competed and non-competed lines.
Protein kinase receptor i19VEGFR-1 binds and 
activates Src-protein kinases
We have previously reported that i21VEGFR-1 in 
MDA-MB-231 breast cancer cells was able to enhance 
phosphorylation of Src [20]. Because the i
19
VEGFR-1 
is slightly larger and contains all the i21VEGFR-1 
domains, we reasoned that it too would enhance Src 
phosphorylation. Co-transfection of CHO cells or HEK293 
cells with recombinant plasmids containing the coding 
sequences for i
19
VEGFR-1 and Src, produced a remarkable 
phosphorylation of tyrosine Y418, and so activation of SRC 
(Figure 6A). The increase in Y418 phosphorylation is much 
more lower when Src is transfected without i
19
VEGFR-1.
Moreover, after over-expressing Flag tagged-
i
19
VEGFR-1 with Src (or Fyn) kinase by cell co-
transfection we detected more Src (or Fyn) protein bound 
to the anti-flag resin beads when Flag tagged-i
19
VEGFR-1 
protein was present (Figure 6B), suggesting binding of 
i
19
VEGFR-1 to Src and Fyn kinases.
Sequence elements that may induce i19VEGFR-1 
and i28VEGFR-1 transcription
The two isoforms, i
19
VEGFR-1 and i
28
VEGFR-1, 
originate at an alternative transcriptional start site (aTSS) 
in introns 19 and 28, respectively, of the full-length 
VEGFR-1 receptor.
We took advantage of the huge amount of available 
information (Encode/Jaspar/Consite) and searched in silico 
for potential DNA binding elements and chromatin cues 
that allowed i
19
VEGFR-1 and i
28
VEGFR-1 transcription 
in testis (Figure 7). The sequence RGGTCA, to which 
CREM factors, nuclear factors and RORα transcription 
factors can bind, was over-represented relatively to 
RCGTCA, the canonical half-CRE site [23]. A putative p53 
responsive element [22] (marked in red in Figure 7A), with 
Figure 3: Northern blot pattern of VEGFR-1 from total RNA expressed in mature testis, cryptorchid testis and 
HUVEC cells as indicated. Agarose-formaldehyde gel blotted and hybridized using a probe complementary to the kinase domain. RNA 
loads correspond to 40 μg (left lane) or 20 μg (all other lanes) of total RNA. 3′L and 3′S denote i
19
VEGFR-1 and i
28
VEGFR-1 transcripts, 
displaying either, whole length or shorter (675 nt) 3′UTR, respectively. Bottom panel: Ribosomal staining as a visual indicator of sample 
loading.
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Figure 4: Expression of VEGFR-1 variants analyzed by manual, semi-quantitative and real-time PCR. (A and C) 
Ethidium bromide image of a 1.5% agarose gel. (B, D and E) Real time-PCR quantification relative to β-actin, showing standard deviation. 
(F) Statistical Bar Graph showing relative expression values of i
19
VEGFR-1 in spermatozoa, relative to β-actin and referred to i
19
VEGFR-1 
levels in mature testis (2-ΔΔ Ct). The pool of sperm defective samples (see methods), n = 15 shows a significantly decreased (**p < 0.0003) in 
i
19
VEGFR-1 expression when compared with the pool of non-defective spermatozoa (n = 16, normal) by the same parameters. VEGFR-1, 
full-length (FL) transmembrane (TM) receptor, sVEGFR-1 (s13), s14VEGFR-1 (s14).
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a 9 nucleotides stalk and 7 nucleotides loop is located just 
after the TSS of the i
19
VEGFR-1 gene, and is preceded (23 
nucleotides before) by another palindrome with the stalk of 
the RGGTCA sequence just mentioned (Figure 7A).
The transcription start sites, Hot Spots for 
transcription activation, CpG islands, DNase hypersensitive 
peak clusters, and Histone H3 Lys27 acetylation 
(H3K27ac) marks around the aTSS of i
19
VEGFR-1 and 
i
28
VEGFR-1 are shown in Figure 7. Worth mentioning, 
are binding sites for Sox17 and Sox5, pioneering 
transcription factors involved in post-meiotic remodeling 
and over-represented near the aTSS of the i
19
VEGFR-1 and 
i
28
VEGFR-1. Also the Spz1 transcription factor, located 
in both i
19
VEGFR-1 and i
28
VEGFR-1 promoter regions, 
that functions as a spermatogenic Zip Protein relevant for 
spermatogenesis.
DISCUSSION
Two transcript variants, i
19
VEGFR-1 and 
i
28
VEGFR-1, of the VEGFR-1 receptor, missing the 
extracellular and transmembrane domains and therefore 
intracellular and independent of ligands, are predominantly 
expressed, over the complete transmembrane transcript 
and soluble variants of the VEGFR-1 gene, in mature 
testis and human sperm cells. The two isoforms start 
TATA-less transcription in introns 19 and 28, respectively, 
in rich polypyrimidine stretches, a characteristic shared 
by transcripts without a TATA-box [24] and incorporate 
leader sequences from the respective introns were 
transcription starts. The palindromic p53 element [22] 
in the i
19
VEGFR-1 transcripts (nucleotides 2 to 22) 
may confer regulatory potential after transcription. The 
presence in the i
19
VEGFR-1 transcript of out-of-frame 
uORFs in the 5′UTR (Figure 1), may also modulate 
translation and stabilize the transcripts [25, 26].
We have previously observed that several genes 
selectively expressed during spermatogenesis use 
alternative transcription start sites and alternative 
splicing, giving raise to differential 5′ and 3′ regions. Also 
shorter 3′UTRs, by eliminating destabilizing sequences, 
give rise to more stable transcripts [3, 4]. In the case of 
i
19
VEGFR-1 and i
28
VEGFR-1 isoforms, shorter 3′UTRs 
are predominantly expressed (Figure 2). Shortening of 
the 3′UTR in VEGFR-1, eliminates a distal GT-repeat 
sequence of the VEGFR-1 receptor that is considered a 
determinant of allele instability [27].
Cryptorchid testis, having just spermatogonia germ 
cells and lacking differentiated spermatogenic cells, do 
not express i
19
VEGFR-1 and i
28
VEGFR-1 isoforms. In 
addition, both isoforms are enriched in spermatozoa 
relatively to mature testis.
We found a statistically significant (p < 0.0003) higher 
expression of i
19
VEGFR-1 mRNA in the spermatozoa of men 
with normal semen parameters [21] compared to asteno, oligo 
or oligoastenozoospermic patients, suggestive of a role for 
i
19
VEGFR-1 in male fertility; however, we are cautious and 
larger clinical studies are to be done to confirm these data.
Table 2: Antibodies used
Primary 
Antibodies
Host 
species
Reactivity/cross-
reactivity Dilution Company Clonality
Anti-VEGFR-1
#2893
Rabbit
Human/do not cross-
react with VEGFR-2 
or VEGFR-3, neither 
with sVEGFR-1
1:1000 Cell Signaling
Polyclonal against 
residues surrounding 
Thr 1307
Src #2108 Rabbit Human and other species 1:1000 Cell Signaling
Polyclonal against 
residues close to the 
carboxylate terminus of 
human Src
Phospho-Src
(Tyr 418)
# 44-660G, RRID
AB_2533714
Rabbit Human and other species 1:1000
Invitrogen/
ThermoFisher Scientific
Polyclonal against PY418
Flt-1 C-17 
#Sc-316
Rabbit Human and other species 1:200
Santa Cruz 
Biotechnology
Polyclonal against 
C-terminus
Fyn3 
#sc16
Rabbit Human and other species 1:300
Santa Cruz 
Biotechnology Polyclonal
Anti-β Actin
#A5316
Mouse Human and other species 1:5000 Sigma Monoclonal
Anti α-Tubulin
#T6074
Mouse Human and other species  2 ng/mL Sigma
Monoclonal
epitope at C-terminal
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The i
19
VEGFR-1 transcripts translate to a protein 
of 49kD (Figure 5). The i
19
VEGFR-1 protein is a little 
bigger, but similar in domains′ conservation to the isoform 
expressed in cancer cells [20]. Both truncated kinases 
activate the Src protein kinase and are very similar to 
Tr-KIT, a truncated variant of the c-KIT protein kinase, 
essential for sperm DNA integrity and proposed as a 
marker of human sperm quality [28], also important for 
activation of the parthenogenesis [29]. The i
19
VEGFR-1 
kinase matches the Tr-KIT as it also conserves the 
phosphotranspherase-domain and the carboxy-terminal tail 
of the full-length protein. Without the ATP binding site, it 
lacks autophosphorylation ability. Anyway, i
19
VEGFR-1 
induces a robust phosphorylation and activation of the Src 
kinases, as we have demonstrated through cotransfection 
of cells with both recombinant constructs (Figure 6).
Haploid expression depends on short stretches 
located close to the aTSS [30, 31], and truncation and 
the utilization of cryptic intragenic promoters has been 
proposed as a transcriptional signature of the germ 
cells undergoing terminal differentiation [5, 30]. This 
frequently involves the use of transcription factors like 
CREMτ (cAMP response element modulator tau) and 
GCNF (germ cell nuclear factor). These factors use an 
overlapping DNA binding site that is sufficient to direct 
cell type-specific expression in vivo [23, 32]. The same 
binding element is used by the transcription factor RORα 
[33] and is present several times in both i
19
VEGFR-1 and 
i
28
VEGFR-1 regulatory region (Figure 7). A palindromic 
p53 conserved DNA binding element in i
19
VEGFR-1 is 
not only found in the gene, it is also incorporated within 
the first 23 nucleotides (from 2 to 22) of the transcript 
and may form a hairpin structure (Figure 7A). Manual and 
in silico analysis of the regions around i
19
VEGFR-1 and 
i
28
VEGFR-1 aTSS, demonstrated an extensive repertoire 
of DNA binding sites, hot-spots, high density CpG Island, 
DNase hypersensitive peak clusters, and protein marks in 
both genes (Figure 7). These DNA regions may allow for 
chromatin opening and expression of the mRNA in testis 
cells. Worth mentioning are the presence of specific DNA 
binding sequence elements in the proximal promoters of 
these isoforms, like Sox17, Sox5 or Spz1 binding sites 
(Figure 7). Sox5 has been found within the nucleus of 
mouse post-meiotic round spermatids [34]. Sox17 is 
Figure 5: Western blot analysis of i19VEGFR-1 (p49) (49kDa) and putative i28VEGFR-1 (p9.5) (9.5kDa) isoforms 
expressed in normal sperm samples. Detection was carried out with the anti-VEGFR-1 antibody sc-316 from Santa Cruz, and 
validated by competition with a specific peptide (see methods). At left, molecular weight markers BioRad. The cropped part of the blot 
correspond to a disturbing unspecific artifact present in both, competed and non-competed lines.
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Figure 6: Western blot analysis showing transphosphorylating activity and binding of i19VEGFR-1 on Src kinases. (A) 
Cells (CHO-cells) were either, non-transfected, transfected (TC) with recombinant GFP plus Src recombinant plasmid (RPT), or transfected 
with Src recombinant plasmid (RP plus flag-tagged i
19
VEGFR-1 RP). The detecting antibodies, anti-Src, Anti-SrcY418-P (phosphorylated 
activating Y residue) and anti-β-Actin, are shown at right. The β-actin was used as the loading control. (B) Binding experiments to assess 
physical interaction between i
19
VEGFR-1 and SRC (FYN) kinases. Either, protein extracts over-expressing only active SRC or FYN 
kinases (TC, Transfected cells) or one of this kinases plus i
19
VEGFR-1 tagged to flag, were assayed for binding to and Anti-flag gel as 
described (see methods). Detecting antibodies are shown at left. 
detected in about 10% of all testis specific genes [35], 
and Spz1, a spermatogenic Zip regulatory Protein [36], 
is drastically reduced in meiotic cells of oligozoospermic 
infertile men [37].
Given the conserved prevalence of truncated 
isoforms, preferentially truncated tyrosine kinases 
[5], within the spermiogenic transcriptome, truncated 
receptor kinases i
19
VEGFR-1 and i
28
VEGFR-1 may play 
a relevant role in and after the post-meiotic stages of 
spermatogenesis. From the drastic remodeling processes 
that the cells undergo to become spermatozoa until the 
sequential remodeling of the plasmatic membrane that 
occur during activation and capacitation. Important 
players in these processes are different truncated kinases 
[5] as well as the SRC-family kinases (SFK) [38], that are 
activated by selective tyrosine phosphorylation. In this 
processes, i
19
VEGFR-1 may be either absolutely required 
or play an important redundant role. Worth mentioning 
is the parallelism that exist between i
19
VEGFR-1 and Tr-
KIT-receptor tyrosine kinases. Both belong to the same 
subclass (Subclass III) of receptor tyrosine kinases [39], 
activate SKFs, and exist in spermatozoa as truncated 
variants of the full transmembrane receptor [28]. 
Although the VEGFR-1 homozygous mice defective for 
the tyrosine kinase domain reaches the second generation 
[40], we believe that the lack of these isoform is a risky 
situation for the correct process of fertilization.
Potential mechanisms to explain why the 
expression of the i
19
VEGF isoform may be repressed 
in infertile semen samples, may be found at the 
genome level or at the stability of the mRNA. At the 
genome level, either, mutations in the enhancers or 
promoters of pioneers or other specific transcription 
factors, may affect negatively the expression program 
that develops during differentiation of spermatogenic 
cells, decreasing the levels of truncated isoforms 
like i
19
VEGF. In addition, mutations in the coding 
regions of the same factors, implied in TSS selection 
and splicing may affect their ability to produce these 
alternate isoforms.
In conclusion, the two i
19
VEGFR-1 and i
28
VEGFR-1 
isoforms, by taking advantage of the intron-exon 
architecture of the VEGFR-1 gene and the opening of 
intronic platforms for transcription, are the predominant 
VEGFR-1 isoforms expressed in spermatogenic cells. 
They can be expressed as proteins without any dependence 
on ligands, and in the case of i
19
VEGFR-1, it manifests a 
strong ability to phosphorylate and activate Src kinases, 
critical for sperm capacitation and fertility. Altogether, 
i
19
VEGFR-1, either critical or redundant to other truncated 
kinases like Tr-KIT, may be an important device for sperm 
remodeling, capacitation and fertilization. Further clinical 
studies are needed to extend the significance of these 
VEGFR-1 isoforms as markers of human infertility.
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Figure 7: (A) In silico reported elements around the TSS (arrow) of i
19
VEGFR-1 gene. Two palindromic sequences, spaced by 23 
nucleotides, first one with the stalk of the RGGTCA sequence (see results) and the second one with a p53 responsive element (RE) [22] (in 
red), are depicted at the top of the Figure. The p53 palindrome is just placed at the transcription start site (TSS) of i
19
VEGFR-1. Vertical 
lines depict DNA response elements, located in the proximal promoter and first intron. DNase I hypersensitivity hot spots (rectangles in 
first intron), CpG islands (rectangles in proximal promoter and first intron) and H3K27ac marks (waves decreasing in height towards the 
first i
19
VEGFR-1 intron) are highlighted in color. (B) In silico reported elements around the TSS (arrow) of i
28
VEGFR-1 gene. Vertical lines 
depict DNA response elements located in the proximal promoter and first intron. Location of hot spots (consecutive rectangles around the 
TSS), CpG island (rectangle in the first intron), and DNase I hypersensitivity peak clusters (rectangles around the TSS and at the end of the 
i
28
VEGFR-1 first intron) are highlighted in color.
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MATERIALS AND METHODS
Semen samples and cryptorchidic testis
Samples were obtained after informed consent, 
from sperm donors and patients from the Andrology Unit 
of the Hospital Clinic of Barcelona, and classified as 
normozoospermic, astenozoospermic, oligozoospermic 
or oligoastenozoospermic according to WHO 2010 
parameters [21]. A total of 31 samples were individually 
processed to obtain total RNA, then reverse transcribed 
and quantified by real-time PCR to analyze expression. 
A total of 15 samples where considered defective, in 
number or linear motility as just mentioned, and grouped 
for statistical analysis to be compared to a pool of 16 non-
defective samples (named normal) (Figure 4) by the same 
parameters. The pool of defective samples comprised: 
10 astenozoospermic (A), 2 oligozoospermic (O) and 3 
oligoastenozoospermic (OA) samples.
Semen was processed as described by De Mateo 
et al., 2007 [41]. Cell count was carried out with a 
Neubauer chamber.
Cryptorchidic testis was obtained from a patient 
undergoing surgical preventive intervention. The 
histological study of this cryptorchidic testis indicated 
complete absence of differentiated spermatogenic cells 
with presence of only somatic cells and spermatogonia.
RNA/cDNA, electrophoresis, northern 
hybridization, and probes
Human normal testis total RNA was obtained 
from Clontech (mixed population of men aged 14-
60). Two different batches were tested. The cDNA was 
prepared from this RNA, either, by reverse transcription 
(SuperScript III Reverse Transcriptase cat. no. 18080-093) 
or by One-Step RT-PCR (Qiagen cat. no. 210212).
Human total spermatozoa RNA (see Ethics 
statement) was prepared with the TriPure Isolation reagent 
(Roche), and/or RNeasy silica-membrane spin-columns 
(Qiagen) following the manufacturer instructions.
Cryptorchidic testis was immediately frozen and 
reduced to a homogenous powder (mortar) in liquid 
nitrogen. Total RNA was extracted with TriPure Isolation 
reagent, followed by further purification in RNeasy silica-
membrane spin-columns (Qiagen), as before.
The procedure used for electrophoresis, northern 
blot, and preparation of DNA probes has been previously 
described [20].
Human VEGFR-1 kinase-domain primers (Table 1) 
were used to obtain a probe that hybridized with the full-
length VEGFR-1 mRNA and any VEGFR-1 containing the 
whole or part of the kinase domain and C-tail.
RACE5′ and RACE3′
The Human Testis Marathon-Ready cDNA 
(Clontech cat. no. 639314) for rapid amplification of 
cDNA ends (RACE), the primers included in the kit and 
specific ones for the specific isoforms (ThermoFisher 
Scientific, Table 1), as well as the conditions recommended 
by the manufacturer, were used.
DNA sequencing
Sequencing was conducted with the BigDye 
Terminator v3.1 (Applied Biosystems), as previously 
described, [20] and analyzed at the Autonomous 
University of Barcelona (CRAG Genomic Centre).
The nucleotide sequences of i
19
VEGFR-1 and 
i
28
VEGFR-1 isoforms were deposited in the GenBank 
database under accession numbers JF509744 and JF509745.
Recombinant clones, cloning, electro-
transformation, and DNA preparation
Human Src recombinant clone was from OriGene 
Technologies and contained v-Src sarcoma transcript 
variant 1 (NM_005417) in pCMV6-XL4. Human Fyn-
recombinant clone was also from OriGene (NM_002037).
The i
19
VEGFR-1 coding region followed by the 
flag-tag were inserted into the pcDNA3.1(+) vector 
(Invitrogen) after enrichment by amplification from 
human testis cDNA with the primers: 19EAT, HFFP and 
HFFFA (Table 1). Restriction enzymes sites as well as the 
flag coding sequence, as indicated in Table 1 preceded 
the specific sequences in the primers. The inserted 
i
19
VEGFR-1 coding region was then flanked by specific 
restriction sites, for polarity cloning into the vector, and 
tagged with the Flag sequence. The recombinants having 
the expected insert size, were confirmed by sequencing, 
and high quality DNA was prepared (Qiagen) for 
subsequent eukaryotic transfection.
RT-PCR and quantitative real-time PCR
Total RNA was reverse transcribed to cDNA with 
the iScript cDNA synthesis kit (BioRad) and specific 
primers, random nanomers or anchored oligo(dT). 
Manual (Ecogen) and semi-quantitative RT-PCR, was as 
previously described [20]. Real-Time PCR was performed 
with an ABI 7500. Specific primers expanding at least one 
exon were used (Table 1). Experiments where performed 
in duplicated, and repeated three times.
Statistical analysis
Values are expressed as mean and standard 
deviations. Comparisons were made by the Wilcoxon test.
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Antibodies, SDS-PAGE, and western blotting
Antibodies and blocking peptide. Anti-Flt-1 #2893 
(Cell Signalling); anti-Flt-1 (C-17): sc-316 (Santa Cruz) 
(blocking peptide, sc-316P Santa Cruz); anti-Src #2108 
(Cell Signalling); anti-phospho-Src (pY418) 44-660G 
(Invitrogen/Thermo Fisher Sc); anti-Fyn antibody FYN3 
#sc-16 (Santa Cruz); anti-β-actin A5316 (Sigma) (loading 
control); anti-α−tubulin T6074 (Sigma) (loading control). 
See Table 2 for antibodies’ additional details.
Western blot
Cells were collected 48 h after transfection and lysed 
in lysis buffer, subjected to NuPAGE® Novex® Bis-Tris gels 
and NuPAGE® MES SDS gels, blotted in Nitrocellulose 
membranes (ThermoFisher) and hybridized with specific 
antibodies as recommended. Results were confirmed after 
performing three independent experiments.
Total human normal testis protein was from 
Clontech, pooled from 18 adult males aged 19-64. Semen 
samples were extracted for protein using Chaps or 0.5% 
Nonidet P-40 lysis buffer.
Peptide competition. Anti-Flt-1 Antibody (Santa 
Cruz) was diluted in tris-buffered saline (TBS) with or 
without the competing peptide at 200M fold excess as 
recommended (Santa Cruz).
Binding experiments
Cells. CHO and HEK293 Cells (Dr. Carles Enrich, 
Faculty of Medicine, UB), HUVEC Cells (Dr. Teresa 
Royo, Faculty of Medicine, UB) were cultured in RPMI-
10% FBS, DMEM-10% FBS or supplemented Medium 
200 (Gibco) respectively.
DNA constructs transfection. CHO cells or HEK293 
cells were seeded in 100 mm culture plates (Corning) 
at a density of 3.5 × 106 cells/plate and cultured with 
RPMI-10% FBS. Transfections were performed with 
Lipofectamine® 3000 Reagent (ThermoFisher) and 5 µg 
of each recombinant DNA. GFP transfected cells were 
used as a control.
Affinity gel binding and sedimentation. Anti-Flag 
(DYKDDDDK) affinity gel from Biotools was used for 
protein capture and interaction analysis, as recommended. 
Briefly, proteins were extracted with 1% Triton X-100, and 
500 μL were allowed to interact with 10 μL of uniformly 
resuspended anti-Flag affinity gel in 600 μL Tris-buffered 
saline (TBS), for 2 h at 4°C and with gently agitation. Then, 
the resin was collected by centrifugation (30 sec at 4,000xg) 
and washed (3–5 times) with 0.5 mL of TBS till OD280 was 
<0.05. Elution was carried with 2xSDS PAGE, boiled for 5 
min and 4 μL loaded in SDS-PAGE gels. The experiment 
was reproduced 3 times with independent samples.
In silico analysis
VEGFR-1 genomic sequences were analyzed 
for potential transcription factor binding sites using the 
JASPAR software [42] for single sequences and Consite 
software [43].
CpG islands in the VEGFR-1 gene were predicted 
using DBCAT (DataBase of CpG islands and Analytical 
Tool) software [44].
DNaseI hypersensitivity in the VEGFR-1 locus 
was analyzed comparing against the ENCODE genomic 
region derived from assays in the cell line NT2-D1 cell 
[NTERA-2 cl.D1 [NT2/D1] (ATCC® CRL-1973) from 
testis, with the data deposited in the GenomeBrowser [45].
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